Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon

M. Lisker-Melman; D. Webb; A. M. Di Bisceglie; C. Kassianides; P. Martin; V. Rustgi; J. G. Waggoner; Y. Park; J. H. Hoofnagle

doi:10.7326/0003-4819-111-6-479

Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon

M. Lisker-Melman
, D. Webb
, A. M. Di Bisceglie
, C. Kassianides
, P. Martin
, V. Rustgi
, J. G. Waggoner
, Y. Park
, J. H. Hoofnagle

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

A high proportion of patients with HBV-related glomerulonephritis will respond to a 4-month course of alpha-interferon with a clinical, biochemical, and serologic remission.

Original language	English
Pages (from-to)	479-483
Number of pages	5
Journal	Annals of internal medicine
Volume	111
Issue number	6
DOIs	https://doi.org/10.7326/0003-4819-111-6-479
State	Published - Jan 1 1989

Access to Document

10.7326/0003-4819-111-6-479

Cite this

@article{0ea9461ad6f04416b28911846351a5cc,

title = "Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon",

abstract = "A high proportion of patients with HBV-related glomerulonephritis will respond to a 4-month course of alpha-interferon with a clinical, biochemical, and serologic remission.",

author = "M. Lisker-Melman and D. Webb and \{Di Bisceglie\}, \{A. M.\} and C. Kassianides and P. Martin and V. Rustgi and Waggoner, \{J. G.\} and Y. Park and Hoofnagle, \{J. H.\}",

year = "1989",

month = jan,

day = "1",

doi = "10.7326/0003-4819-111-6-479",

language = "English",

volume = "111",

pages = "479--483",

journal = "Annals of internal medicine",

issn = "0003-4819",

number = "6",

}

TY - JOUR

T1 - Glomerulonephritis caused by chronic hepatitis B virus infection

T2 - Treatment with recombinant human alpha-interferon

AU - Lisker-Melman, M.

AU - Webb, D.

AU - Di Bisceglie, A. M.

AU - Kassianides, C.

AU - Martin, P.

AU - Rustgi, V.

AU - Waggoner, J. G.

AU - Park, Y.

AU - Hoofnagle, J. H.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - A high proportion of patients with HBV-related glomerulonephritis will respond to a 4-month course of alpha-interferon with a clinical, biochemical, and serologic remission.

AB - A high proportion of patients with HBV-related glomerulonephritis will respond to a 4-month course of alpha-interferon with a clinical, biochemical, and serologic remission.

UR - https://www.scopus.com/pages/publications/0024447367

U2 - 10.7326/0003-4819-111-6-479

DO - 10.7326/0003-4819-111-6-479

M3 - Article

C2 - 2774373

AN - SCOPUS:0024447367

SN - 0003-4819

VL - 111

SP - 479

EP - 483

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 6

ER -

Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon

Abstract

Access to Document

Other files and links

Fingerprint

Cite this